Cusums to Measure Chronic Daily Headache

Freidank‐Mueschenborn, Edda; Fox, Anthony W.

doi:10.1111/j.1526-4610.2006.00299.x

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 3‐substituted indole is a basic building block of vasoconstrictor hormone serotonin which plays important function of conducting impulses to the brain [5] . Also, there are several drugs which resembles to 3‐substituted indole class, such as sumatriptan, [6] ondansetron, [7] and alosetron [8] used in the treatment of migraine, suppression of nausea caused by cancer chemotherapy and radiotherapy, and for the treatment of irritable bowel syndrome respectively. The indol‐3‐ylacetic acid derivatives are renowned synthetic plant growth regulating hormones and they are also used to treat rheumatoid arthritis [9] .…”

Section: Introductionmentioning

confidence: 99%

Selective one pot multicomponent green synthesis of 3‐[(aryl)(arylthio)methyl]‐1H‐indole derivatives utilizing enhanced Lewis acidic sites of Surfactant‐assisted ZnO catalyst

et al. 2023

View full text Add to dashboard Cite

Five different ZnO nanocrystallites (ZnO‐1 to ZnO‐5) were successfully synthesized by a surfactant‐assisted hydrothermal technique using various surfactants. All the ZnO nanocrystallites are thoroughly characterized by XRD, IR, UV‐DRS spectroscopy and FESEM‐EDS analysis. Among the synthesized ZnO nanocrystallites, the CTAB‐assisted synthesized ZnO‐4 exhibited a fine disc‐like morphology with a minimum crystallite size (23 nm). Subsequent to reaction optimization studies, the ZnO‐4 is utilized as an efficient catalyst for one pot‐three component green synthesis of 3‐[(aryl)(arylthio)methyl]‐1H‐indoles (4a–4p) via. condensation of a variety of indoles, aromatic aldehydes and aromatic thiols at room temperature in water. The single‐crystal X‐ray structure of 3‐[(phenyl)(phenylthio)methyl]‐1H‐indole (4a) is also been reported (CCDC 2170437). The Lewis acidic property of the catalyst‐supported probable mechanism is well proposed subsequent to pyridine‐IR studies of the ZnO catalysts. Indeed, CTAB‐assisted synthesized ZnO‐4 was found to be most effective and selective Lewis acid catalyst for the synthesis of a variety of 3‐[(aryl)(arylthio)methyl]‐1H‐indole derivatives in water at ambient temperature with merits like higher yields, lower reaction time, catalyst recovery and reuse.

show abstract

Section: Introductionmentioning

confidence: 99%

Selective one pot multicomponent green synthesis of 3‐[(aryl)(arylthio)methyl]‐1H‐indole derivatives utilizing enhanced Lewis acidic sites of Surfactant‐assisted ZnO catalyst

et al. 2023

View full text Add to dashboard Cite

show abstract

Monitoring patients using control charts: a systematic review

Tennant

Mohammed

Coleman

et al. 2007

International Journal for Quality in Health Care

View full text Add to dashboard Cite

show abstract

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine

Silberstein

Dodick²,

Lindblad

et al. 2012

Neurology

View full text Add to dashboard Cite

Objective: To assess the efficacy and safety of adding propranolol to topiramate in chronic migraine subjects inadequately controlled with topiramate alone. Methods:This was a double-blind, placebo-controlled, randomized clinical trial conducted through the National Institute of Neurological Disorders and Stroke Clinical Research Collaboration, expected to randomize 250 chronic migraine subjects inadequately controlled (Ն10 headaches/ month) with topiramate (50-100 mg/day) to either propranolol LA (long acting) (240 mg/day) or placebo. Primary outcome was 28-day moderate to severe headache rate reduction at 6 months (weeks 16 to 24) compared with baseline (weeks Ϫ4 to 0). Results:A planned interim analysis was performed after 48 sites randomized 171 subjects. The data and safety monitoring board recommended ending the trial after determining that it would be highly unlikely for the combination to result in a significant reduction in 28-day headache rate compared with topiramate alone if all 250 subjects were randomized. No safety concerns were identified. At study closure, 191 subjects were randomized. The 6-month reduction in moderate to severe 28-day headache rate and total 28-day headache rate for combination therapy vs topiramate alone was not significantly different: 4.0 vs 4.5 days (moderate to severe 28-day headache rate; p ϭ 0.57) and 6.2 vs 6.1 days (total 28-day headache rate; p ϭ 0.91). Conclusions:This study does not provide evidence that the addition of propranolol LA to topiramate adds benefit when chronic migraine is inadequately controlled with topiramate alone. Classification of evidence:This study provides Class II evidence that propranolol LA, added to topiramate, is ineffective in chronic migraine patients who fail topiramate monotherapy. Neurology

show abstract

Cusums to Measure Chronic Daily Headache

Abstract: Cusums can be useful tools for detecting change in CDH, whether at the level of the clinical trial or when managing patients using stepped-care treatment algorithms.

Cited by 3 publications

References 7 publications

Selective one pot multicomponent green synthesis of 3‐[(aryl)(arylthio)methyl]‐1H‐indole derivatives utilizing enhanced Lewis acidic sites of Surfactant‐assisted ZnO catalyst

Selective one pot multicomponent green synthesis of 3‐[(aryl)(arylthio)methyl]‐1H‐indole derivatives utilizing enhanced Lewis acidic sites of Surfactant‐assisted ZnO catalyst

Monitoring patients using control charts: a systematic review

Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine

Contact Info

Product

Resources

About